Ocugen announce Phase 3 enrolment completion for OCU400, the largest gene agnostic therapy trial for RP
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Search results
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Join our as our young adults share their lived experiences of navigating inherited sight loss.
The latest webinar from Retina UK.
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.
The project aims to develop a cost effective method of examining the entire ABCA4 gene to look for variations that might cause disease.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
Different inherited sight loss conditions present noticeable symptoms at different times.